The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

The findings from the new study, published in The American Journal of Pathology ... including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can ...

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for ...

The primary histology endpoint ... showed regression of liver fibrosis based on three orthogonal measures: ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), 30% ...

both conventional and AI-assisted histology, suggest improvements in fibrosis in patients treated with icosabutate,” said Arun Sanyal, M.D., Director of the Stravitz-Sanyal Institute for Liver ...

Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex ... reduce non-invasive markers of fibrosis and liver injury, and improve insulin sensitivity and lipoprotein profile.